Anti-Mouse CD29 (Clone KMI6) – Biotin

Anti-Mouse CD29 (Clone KMI6) – Biotin

Product No.: C1103

- -
- -
Clone
KMI6
Target
CD29
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
Integrin beta-1, Fibronectin receptor subunit beta, VLA-4 subunit beta
Isotype
Rat IgG2a κ
Applications
ELISA
,
EM
,
FA
,
FC
,
IF Microscopy
,
IP
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Rat
Immunogen
B cell-supportive stromal cell line BMS2
Product Concentration
0.5 mg/ml
Formulation
This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
State of Matter
Liquid
Storage and Handling
This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 – 8° C Wet Ice
Additional Applications Reported In Literature ?
ELISA,
EM,
FA,
FC,
IF microscopy,
IP,
WB
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
KMI6 activity is directed against mouse CD29, also known as integrin beta 1.
Background
Stromal cells are needed for the early steps of B lymphocyte differentiation and proliferation1. CD29, also known as integrin beta 12, is a 110 kDa protein discovered due to its expression on bone marrow stromal cells, at cell surface areas that interact with undifferentiated lymphoid cells1. Integrin beta 1 is a member of a family of alpha beta heterodimers that act as cell surface receptors for extracellular matrix proteins3, including collagen, fibronectin, fibrinogen, laminin, VCAM1, and vitronectin among others4. CD29 is also involved in sperm-egg fusion. Through these interactions, CD29 regulates and/or promotes cell adhesion, laminin matrix deposition, endothelial cell motility, angiogenesis, osteoblast compaction, the formation of mineralized bone nodules, and cytokinesis.

KMI6 was raised against the B cell-supportive stromal cell line BMS21. LOU/MN rats were immunized with BMS2 cells and subsequently spleen cells were fused with murine Sp2/0 for hybridoma generation. Antibody recognition is insensitive to the glycosylation state but is lost when the CD29 protein is reduced for Western blotting2. As such, the epitope is likely conformation-dependent. KMI6 was used to identify CD292. KMI6 can enhance cell adhesion of fibronectin to CD4 -8- thymocytes3.
Antigen Distribution
CD29 is present on the plasma membranes of many stromal cells, bone marrow stromal cell line BMS2 in vitro, and a small number of cells in bone marrow cell suspensions from adult mice. CD29 is also expressed in the media layer of the arterial wall. CD29 is expressed in skeletal and cardiac muscles. CD29 is also constitutively expressed by some immature thymocytes. CD29 can be slightly induced on mature thymocytes and peripheral T cells by activation with Con A.
Ligand/Receptor
Alpha-1, alpha-2, alpha-3, alpha-4, alpha-5, alpha-6, alpha-7, alpha-8, alpha-9, alpha-10, alpha-11 or alpha-V, collagen, fibronectin, fibrinogen, laminin, VCAM1, and vitronectin among other
NCBI Gene Bank ID
UniProt.org
Research Area
Cell Adhesion
.
Immunology
.
Integrin

References & Citations

1. Jacobsen K, Miyake K, Kincade PW, et al. J Exp Med. 176(4):927-935. 1992.
2. Wu X, Miyake K, Medina KL, et al. Hybridoma. 13(5):409-416. 1994.
3. Wadsworth SA, Chang AC, Hong MJ, et al. J Immunol. 154(5):2125-2133. 1995.
4. https://www.uniprot.org/uniprotkb/P09055/entry
Indirect Elisa Protocol
EM
FA
Flow Cytometry
IF Microscopy
Immunoprecipitation Protocol
General Western Blot Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.